RecruitingPhase 2NCT06980805

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Studying Chronic cutaneous lupus erythematosus

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Immunovant Sciences GmbH
Intervention: IMVT-1402(drug)
Enrollment: 56 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (30)

Site Number - 1010, Anniston, Alabama, United States
Site Number - 1020, Birmingham, Alabama, United States
Site Number - 1038, Phoenix, Arizona, United States
Site Number - 1034, Scottsdale, Arizona, United States
Site Number - 1022, Beverly Hills, California, United States
Site Number - 1018, Chula Vista, California, United States
Site Number - 1039, Corona, California, United States
Site Number - 1005, Fremont, California, United States
Site Number - 1023, Los Angeles, California, United States
Site Number - 1000, Aurora, Colorado, United States
Site Number - 1033, Castle Rock, Colorado, United States
Site Number - 1021, Farmington, Connecticut, United States
Site Number - 1014, Hialeah, Florida, United States
Site Number - 1017, Jacksonville, Florida, United States
Site Number - 1028, Miami, Florida, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06980805 on ClinicalTrials.gov

Other trials for Chronic cutaneous lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Chronic cutaneous lupus erythematosus →

← Back to all trials